- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01790035
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer (LGG)
A Phase I and Randomized Controlled Phase II Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam RT to the abdomen or pelvis to a minimum dose of 4500 cGy is planned.
- Scheduled to receive concurrent administration of fluoropyrimidine chemotherapy (5-FU or capecitabine) during radiation therapy.
- Age ≥ 18 years.
- Life expectancy ≥ 6 months.
- Negative pregnancy test done ≤7 days prior to registration (for women of childbearing potential only).
The following laboratory values obtained ≤ 28 days prior to registration:
- Hemoglobin ≥ 9.0 g/dL
- WBC ≥ 3,500
- Absolute neutrophil count ≥ 1,500
- Platelets ≥ 100,000
- ECOG Performance Status (PS) of 0, 1, or 2.
- Willingness to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment.
- Ability to complete questionnaire(s) alone or with assistance.
- Ability to understand and willingness to sign informed consent.
Exclusion Criteria:
- Previous bowel resection which, in the opinion of the investigator, would decrease the benefit of the probiotic. Patients who have undergone recent bowel surgeries which would not decrease the benefit of the probiotic are eligible provided they are more than 30 days from surgery with no serious complications.
- Known allergy to a probiotic preparation.
- Any history of inflammatory bowel disease.
- Grade 3 or 4 diarrhea, rectal bleeding, abdominal cramping, or incontinence of stool ≤7 days prior to registration.
- Any medical condition that may interfere with ability to receive protocol treatment.
- Prior abdominal or pelvic RT.
- Use of probiotics ≤ 2 weeks prior to registration.
- Use of antibiotics ≤ 3 days prior to registration.
- Planned continuous antibiotic treatment during RT.
- History of gastrointestinal or genitourinary obstruction or porphyria.
- History of irritable bowel syndrome (IBS).
- History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LGG
LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
|
Other Names:
|
Experimental: Placebo
Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
|
|
No Intervention: No intervention
Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT.
These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy (randomized phase II trial)
Time Frame: Up to 6 months following the last dose of LGG or placebo
|
Compare the proportion of patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine being treated with the probiotic LGG who develop CTCAE grade 2 or greater diarrhea to the proportion of patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine being treated with placebo who develop CTCAE grade 2 or greater diarrhea
|
Up to 6 months following the last dose of LGG or placebo
|
Safety (phase I safety lead-in)
Time Frame: Up to 30 days following completion of treatment
|
Determine the safety and tolerability of LGG in patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine The DSMC will review the data as part of an interim analysis when the last patient has had 30 days of follow-up. The DSMC will ensure that at least 18 patients have had follow-up at 30 days (with expected 10% drop-out). Accrual to the randomized portion of the trial will occur only if there are no episodes of lactobacillus associated septicemia. Additionally, if two or more serious adverse events of a similar nature occur and a causal relationship to the investigational product cannot be excluded, accrual to the randomized portion will not occur. |
Up to 30 days following completion of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diarrhea subscale score
Time Frame: Up to 5 years after completion of treatment.
|
The average AUC of the FACIT-D diarrhea subscale scores will be compared between the two treatment groups using a two-sample t-test. The FACIT-D will be completed at baseline, weekly during radiation treatment, for the two weeks following completion of radiation treatment, 12 months following the end of radiation treatment, and years 2-5 following the completion of radiation treatment. |
Up to 5 years after completion of treatment.
|
Need for antidiarrhea medication
Time Frame: Up to 2 weeks after completion of treatment
|
Need for use of an antidiarrheal medication (Loperamide) will be evaluated at a binary endpoint (Use or No Use).
Comparison will be made using Fisher's exact test as previously described (Chitapanarux 2010)
|
Up to 2 weeks after completion of treatment
|
Grade 3 or greater diarrhea
Time Frame: Up to 6 months following the last dose of LGG or placebo
|
In patients receiving abdominal or pelvic chemoradiation with a fluoropyrimidine, compare the proportion of patients who develop diarrhea of grade 3 or greater (by CTCAE version 4.0) in those treated with the probiotic LGG to the proportion in those receiving placebo
|
Up to 6 months following the last dose of LGG or placebo
|
Fecal calprotectin
Time Frame: Up to 2 weeks following the completion of treatment
|
Determine whether fecal calprotectin correlates with onset, duration, and/or severity of diarrhea during chemoradiation
|
Up to 2 weeks following the completion of treatment
|
Serum citrulline
Time Frame: Up to 2 weeks following the completion of treatment
|
Determine whether serum citrulline correlates with onset, duration, and/or severity of diarrhea during chemoradiation
|
Up to 2 weeks following the completion of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Matthew Ciorba, M.D., Washington University School of Medicine
Publications and helpful links
General Publications
- Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol. 2010 Mar;26(2):88-94. doi: 10.1097/MOG.0b013e3283361927.
- Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci. 2009 May;1165:190-4. doi: 10.1111/j.1749-6632.2009.04029.x.
- Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010 May 5;5:31. doi: 10.1186/1748-717X-5-31.
- Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, Walker MR, Marinshaw JM, Stappenbeck TS, Stenson WF. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012 Jun;61(6):829-38. doi: 10.1136/gutjnl-2011-300367. Epub 2011 Oct 24.
- Riehl TE, Alvarado D, Ee X, Zuckerman A, Foster L, Kapoor V, Thotala D, Ciorba MA, Stenson WF. Lactobacillus rhamnosus GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. Gut. 2019 Jun;68(6):1003-1013. doi: 10.1136/gutjnl-2018-316226. Epub 2018 Jun 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201404101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Brigette MaRecruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Henan Cancer HospitalUnknownAdvanced Gastrointestinal TumorsChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States